CTA313 UCAR T Cell Infusion
DrugCAR T cells
NCT Number: NCT07783269
The goal of the ALLNEW clinical trial is to learn if CTA313 UCART is safe and effective for patients with immune mediated disorders.
Participants with SLE, pMS and AIE between the ages of 18 and 75 will be eligible to participate.
Participants will receive one infusion of CTA313 on Day 0. During the Dose Confirmation portion, cohorts will be independently evaluated for safety and to establish the RP2D of CTA313. During the Cohort Expansion portion of the study patients will be evaluated to further confirm the efficacy and safety of CTA313.
Patients will be followed for up to 24 months in this study and will be required to enroll under a separate long term follow up protocol to be followed for up to 15 years.
Trial opening soon.
Get Notified18 year–75 year
All sexes
Interventional
Phase 1
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Key Inclusion Criteria:
Key Exclusion Criteria:
CAR T cells
Time frame: 24 months
Incidence and severity of adverse events including dose limiting toxicities
Time frame: 24 months
Determine the RP2D based on safety, pharmacokinetics/pharmacodynamics, and preliminary efficacy.
Time frame: 24 months
Proportion of participants achieving DORIS and LLDAS
Time frame: 24 months
Proportion of patients without disability progression as defined by change in EDSS
Time frame: 24 months
Proportion of patients achieving functional improvement and/or response by modified Rankin Scale (mRS)
Time frame: 24 months
Evaluate CTA313 cellular pharmacokinetic (PK) by measuring expansion, distribution and persistence
Contact information is provided by the study sponsor or research team.
Imviva Bio
Industry
A Single-Arm, Open-Label, Multi-Center, Phase Ib Basket Study to Evaluate the Safety, Efficacy, and Cellular Pharmacokinetic Profile of CTA313 in Participants With Active Autoimmune Diseases
Acronym: ALLNEW
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07792733
Systemic Lupus Erthematosus (SLE)
View Trial DetailsNCT07729995
Arthritis, Arthritis, Rheumatoid
Boston, Massachusetts, United States
View Trial DetailsNCT07719322
Autoimmune Diseases, Connective Tissue Diseases
Asyut, Assuit, Egypt
View Trial DetailsNCT07593911
Arthritis, Arthritis, Rheumatoid
Beijing, Beijing Municipality, China
View Trial Details